GSK Says Dreamm-3 Phase 3 Study For Blenrep Didn't Meet Primary Endpoint
November 07 2022 - 2:51AM
Dow Jones News
By Michael Susin
GSK PLC said Monday that its Dreamm-3 Phase 3 study in patients
with relapsed or refractory multiple myeloma didn't meet its
primary endpoint of progression-free survival.
The pharmaceutical giant said that the study compared its
monotherapy Blenrep versus pomalidomide in combination with low
dose dexamethasone and observed median progression-free survival
was longer for Blenrep.
"These trials are designed to demonstrate the benefit of Blenrep
in combination treatment with novel therapies and standard-of-care
treatments in earlier lines of therapy and dosing optimization to
maintain efficacy while reducing corneal events," it added.
The company said additional trials will continue and further
data from the studies are anticipated in the first half of
2023.
Write to Michael Susin at michael.susin@wsj.com
(END) Dow Jones Newswires
November 07, 2022 02:36 ET (07:36 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
GSK (NYSE:GSK)
Historical Stock Chart
From Jun 2024 to Jul 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Jul 2023 to Jul 2024